References
- BantelHBergCViethMStolteMKruisWSchulze-OsthoffKMesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitisAm J Gastroenterol200095123452345711151876
- D’IncàRPaccagneMCardinR5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitisWorld J Gastroenterol201319345665567024039359
- De VosMVerdievelHSchoonjansRPraetMBogaertMBarbierFConcentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparationsGut19923310133813421446856
- LichtigerSPresentDHKornbluthACyclosporine in severe ulcerative colitis refractory to steroid therapyN Engl J Med199433026184118458196726
- RachmilewitzDCoated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trialBMJ1989298666682862563951
- DignassALindsayJOSturmASecond European evidence-based consensus on the diagnosis and managementof ulcerative colitis part 2: current managementJ Crohns Colitis2012610991103023040451
- ItoHIidaMMatsumotoTDirect comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized studyInflamm Bowel Dis20101691567157420049950
- FordACKhanKJAchkarJPMoayyediPEfficacy of oral vs topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysisAm J Gastroenterol2012107216717622108446
- MeucciGFasoliRSaibeniSPrognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter studyInflamm Bowel Dis20121861006101021830282
- VelayosFSTerdimanJPWalshJMEffect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studiesAm J Gastroenterol200510061345135315929768
- BernsteinCNNugentZBlanchardJF5-aminosalicylate is not chemo-prophylactic for colorectal cancer in IBD: a population based studyAm J Gastroenterol2011106473173621407180
- FordACKhanKJSandbornWJKaneSVMoayyediPOnce-daily dosing vs conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysisAm J Gastroenterol2011106122070207721894226
- NaganumaMIwaoYOgataHMeasurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazineInflamm Bowel Dis20017322122511515848